Despite significant medical advancements in the oncology space, 30% of patients in the GSK/Harris Poll survey said they never ...

Jefferies lowered GSK (NYSE:GSK) to hold, citing a valuation disconnect between fundamentals and price. Jefferies said it ...

Consumers Rank Nearly 200 Taylor Swift Tracks, Revealing the Commercial Truth Behind Her Last 10 Albums and the True Value of ...

Ongoing Enrollment in Phase 1/2 Trial of Elraglusib in Relapsed/Refractory Ewing Sarcoma with Topline Phase 1 Data Expected ...

GSK has licensed a small molecule for Parkinson's and is teaming up on additional targets for the disease and another ...

The print ads featured a prominent display of a person’s back, highlighting where shingles rashes typically emerge.

Though GSK has put considerable effort into developing pharmacological ... patients’ gaps in access to healthcare,” Mojas ...

GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...

Researchers from University of Washington, Loyola Marymount University, and University of Texas-Austin have published a new ...

This is dangerous on multiple levels and AI Washing, as it is called, is already endemic across the business landscape. For ...

The global glucosamine supplement market is projected to grow from USD 583.6 million in 2023 to USD 932.7 million by 2033, expanding at a CAGR of 4.8%, according to Future Market Insights. The rising ...

Also Read: Just After Pfizer’s RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population Specialty Medicine sales increased ...